Pharmacogenomics: Identification of New Drug Targets
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Human Genetics
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: Mar 22, 2026

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
Published on: September 9, 2022
Pierre-Paul Axisa1, David A Hafler
1aDepartments of Neurology and Immunobiology, Yale School of Medicine, New Haven, Connecticut, USA bCentre National de la Recherche Scientifique, U5282 cCentre de Physiopathologie Toulouse-Purpan, Université Toulouse 3 dINSERM, U1043, Toulouse, France eBroad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
New genetic analysis and biomarkers are revolutionizing the understanding and treatment of multiple sclerosis (MS). These advances offer improved patient care and pave the way for novel therapeutic strategies in managing this complex neurological disease.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: